

# The effect of intravenous fluids on abdominal aortic aneurysm surgery

<b>Submission date</b> 15/12/2007	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 14/02/2008	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 28/05/2014	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Mr Rajiv Vohra

**Contact details**  
Department of Vascular Surgery  
University Hospital Birmingham NHS Trust  
Selly Oak Hospital  
Raddlebarn Road  
Birmingham  
United Kingdom  
B29 6JD

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
N/A

# Study information

## Scientific Title

The anti-inflammatory properties of hydroxyethyl starches during abdominal aortic aneurysm surgery

## Study objectives

That hydroxyethyl starch with a mean molecular weight of 130 kDa (HES130/0.4) has better splanchnic perfusion and thus reduced inflammatory response compared with hydroxyethyl starch of mean molecular weight of 200 kDa (HES200/0.62).

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

South Birmingham Ethics Committee, April 2001, ref: 5600

## Study design

Single-centre unblinded randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Systemic inflammatory response during abdominal aortic aneurysm surgery.

## Interventions

Blood volume expansion with either HES130/0.4, HES200/0.62 or gelatine.

This trial was carried out at Selly Oak Hospital, Birmingham, UK.

## Intervention Type

Drug

## Phase

Not Applicable

**Drug/device/biological/vaccine name(s)**

Hydroxyethyl starch

**Primary outcome measure**

The following were assessed pre-operatively, at aortic clamping, reperfusion and then at regular time points after reperfusion (2, 4, 8, 12, 48, 72, 96 and 120 hours):

Systemic inflammatory response:

1. Serum C-Reactive Protein (CRP)
2. White cell activation
3. Adhesion molecule expression
4. Endotoxin release
5. Splanchnic perfusion

**Secondary outcome measures**

The following were assessed pre-operatively, at aortic clamping, reperfusion and then at regular time points after reperfusion (2, 4, 8, 12, 48, 72, 96 and 120 hours):

1. Renal dysfunction:
  - 1.1. Urinary markers of renal injury
  - 1.2. Serum urea and creatinine
2. Pulmonary dysfunction:
  - 2.1. Lung injury score

**Overall study start date**

01/04/2001

**Completion date**

01/10/2002

**Eligibility****Key inclusion criteria**

All patients undergoing elective infra-renal abdominal aortic aneurysm repair using a transperitoneal route

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Both

**Target number of participants**

60

**Key exclusion criteria**

1. Patients with a history of allergy to any of the study solutions
2. Patients with a creatinine of greater than 177 mmol/L
3. Patients with significant iliac occlusive disease

**Date of first enrolment**

01/04/2001

**Date of final enrolment**

01/10/2002

## **Locations**

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Department of Vascular Surgery**

Birmingham

United Kingdom

B29 6JD

## **Sponsor information**

**Organisation**

Fresenius Kabi (Germany)

**Sponsor details**

Fluid Therapy Division

International Business Centre

Clinical Research

Homburg

Germany

61346-BAD

**Sponsor type**

Industry

**Website**

<http://www.fresenius-kabi.com>

**ROR**

<https://ror.org/01v376g59>

## **Funder(s)**

**Funder type**

Industry

**Funder Name**

Fresenius Kabi (Germany)

## Results and Publications

**Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

**Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/04/2007		Yes	No
<a href="#">Results article</a>	results	01/03/2009		Yes	No